img

Global Myotonic Dystrophy Type 1 (DM1) Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Myotonic Dystrophy Type 1 (DM1) Market Insights, Forecast to 2034

The global Myotonic Dystrophy Type 1 (DM1) market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Myotonic Dystrophy Type 1 (DM1) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Myotonic Dystrophy Type 1 (DM1) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Myotonic Dystrophy Type 1 (DM1) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Myotonic Dystrophy Type 1 (DM1) include Dyne, Audentes, Pfizer, Vertex, PepGen, NeuBase Therapeutics, Lupin, AMO Pharma and Expansion Therapeutics, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Myotonic Dystrophy Type 1 (DM1), sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Myotonic Dystrophy Type 1 (DM1), also provides the sales of main regions and countries. Highlights of the upcoming market potential for Myotonic Dystrophy Type 1 (DM1), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Myotonic Dystrophy Type 1 (DM1) sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Myotonic Dystrophy Type 1 (DM1) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Myotonic Dystrophy Type 1 (DM1) sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Dyne, Audentes, Pfizer, Vertex, PepGen, NeuBase Therapeutics, Lupin, AMO Pharma and Expansion Therapeutics, etc.



By Company


Dyne
Audentes
Pfizer
Vertex
PepGen
NeuBase Therapeutics
Lupin
AMO Pharma
Expansion Therapeutics
Harmony Biosciences
Segment by Type
Exondys
Emflaza
Translarna

Segment by Application


Hospitals
Clinics
Home Care

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Myotonic Dystrophy Type 1 (DM1) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Myotonic Dystrophy Type 1 (DM1) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Myotonic Dystrophy Type 1 (DM1) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Myotonic Dystrophy Type 1 (DM1) Product Introduction
1.2 Market by Type
1.2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Myotonic Dystrophy Type 1 (DM1) Sales Estimates and Forecasts 2018-2034
2.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region
2.2.1 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2018-2024)
2.2.3 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2024-2034)
2.2.4 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2018-2034)
2.3 Global Myotonic Dystrophy Type 1 (DM1) Sales Estimates and Forecasts 2018-2034
2.4 Global Myotonic Dystrophy Type 1 (DM1) Sales by Region
2.4.1 Global Myotonic Dystrophy Type 1 (DM1) Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2018-2024)
2.4.3 Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2024-2034)
2.4.4 Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Myotonic Dystrophy Type 1 (DM1) Sales by Manufacturers
3.1.1 Global Myotonic Dystrophy Type 1 (DM1) Sales by Manufacturers (2018-2024)
3.1.2 Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Myotonic Dystrophy Type 1 (DM1) in 2022
3.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Manufacturers
3.2.1 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Manufacturers (2018-2024)
3.2.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Type 1 (DM1) Revenue in 2022
3.3 Global Key Players of Myotonic Dystrophy Type 1 (DM1), Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Myotonic Dystrophy Type 1 (DM1) Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Myotonic Dystrophy Type 1 (DM1) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Product Offered and Application
3.8 Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Myotonic Dystrophy Type 1 (DM1) Sales by Type
4.1.1 Global Myotonic Dystrophy Type 1 (DM1) Historical Sales by Type (2018-2024)
4.1.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Sales by Type (2024-2034)
4.1.3 Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
4.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type
4.2.1 Global Myotonic Dystrophy Type 1 (DM1) Historical Revenue by Type (2018-2024)
4.2.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Revenue by Type (2024-2034)
4.2.3 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
4.3 Global Myotonic Dystrophy Type 1 (DM1) Price by Type
4.3.1 Global Myotonic Dystrophy Type 1 (DM1) Price by Type (2018-2024)
4.3.2 Global Myotonic Dystrophy Type 1 (DM1) Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Myotonic Dystrophy Type 1 (DM1) Sales by Application
5.1.1 Global Myotonic Dystrophy Type 1 (DM1) Historical Sales by Application (2018-2024)
5.1.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Sales by Application (2024-2034)
5.1.3 Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
5.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application
5.2.1 Global Myotonic Dystrophy Type 1 (DM1) Historical Revenue by Application (2018-2024)
5.2.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Revenue by Application (2024-2034)
5.2.3 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
5.3 Global Myotonic Dystrophy Type 1 (DM1) Price by Application
5.3.1 Global Myotonic Dystrophy Type 1 (DM1) Price by Application (2018-2024)
5.3.2 Global Myotonic Dystrophy Type 1 (DM1) Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Myotonic Dystrophy Type 1 (DM1) Market Size by Type
6.1.1 US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2034)
6.1.2 US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2034)
6.2 US & Canada Myotonic Dystrophy Type 1 (DM1) Market Size by Application
6.2.1 US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2034)
6.2.2 US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2034)
6.3 US & Canada Myotonic Dystrophy Type 1 (DM1) Market Size by Country
6.3.1 US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2034)
6.3.3 US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Type
7.1.1 Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2034)
7.1.2 Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2034)
7.2 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Application
7.2.1 Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2034)
7.2.2 Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2034)
7.3 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country
7.3.1 Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2034)
7.3.3 Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Myotonic Dystrophy Type 1 (DM1) Market Size
8.1.1 China Myotonic Dystrophy Type 1 (DM1) Sales (2018-2034)
8.1.2 China Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034)
8.2 China Myotonic Dystrophy Type 1 (DM1) Market Size by Application
8.2.1 China Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2034)
8.2.2 China Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Myotonic Dystrophy Type 1 (DM1) Market Size by Type
9.1.1 Asia Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2034)
9.1.2 Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2034)
9.2 Asia Myotonic Dystrophy Type 1 (DM1) Market Size by Application
9.2.1 Asia Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2034)
9.2.2 Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2034)
9.3 Asia Myotonic Dystrophy Type 1 (DM1) Sales by Region
9.3.1 Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2018-2034)
9.3.3 Asia Myotonic Dystrophy Type 1 (DM1) Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Type
10.1.1 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Application
10.2.1 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Country
10.3.1 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Dyne
11.1.1 Dyne Company Information
11.1.2 Dyne Overview
11.1.3 Dyne Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Dyne Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Dyne Recent Developments
11.2 Audentes
11.2.1 Audentes Company Information
11.2.2 Audentes Overview
11.2.3 Audentes Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Audentes Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Audentes Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Pfizer Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Vertex
11.4.1 Vertex Company Information
11.4.2 Vertex Overview
11.4.3 Vertex Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Vertex Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Vertex Recent Developments
11.5 PepGen
11.5.1 PepGen Company Information
11.5.2 PepGen Overview
11.5.3 PepGen Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 PepGen Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 PepGen Recent Developments
11.6 NeuBase Therapeutics
11.6.1 NeuBase Therapeutics Company Information
11.6.2 NeuBase Therapeutics Overview
11.6.3 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 NeuBase Therapeutics Recent Developments
11.7 Lupin
11.7.1 Lupin Company Information
11.7.2 Lupin Overview
11.7.3 Lupin Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Lupin Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Lupin Recent Developments
11.8 AMO Pharma
11.8.1 AMO Pharma Company Information
11.8.2 AMO Pharma Overview
11.8.3 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 AMO Pharma Recent Developments
11.9 Expansion Therapeutics
11.9.1 Expansion Therapeutics Company Information
11.9.2 Expansion Therapeutics Overview
11.9.3 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Expansion Therapeutics Recent Developments
11.10 Harmony Biosciences
11.10.1 Harmony Biosciences Company Information
11.10.2 Harmony Biosciences Overview
11.10.3 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Harmony Biosciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Myotonic Dystrophy Type 1 (DM1) Industry Chain Analysis
12.2 Myotonic Dystrophy Type 1 (DM1) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myotonic Dystrophy Type 1 (DM1) Production Mode & Process
12.4 Myotonic Dystrophy Type 1 (DM1) Sales and Marketing
12.4.1 Myotonic Dystrophy Type 1 (DM1) Sales Channels
12.4.2 Myotonic Dystrophy Type 1 (DM1) Distributors
12.5 Myotonic Dystrophy Type 1 (DM1) Customers
13 Market Dynamics
13.1 Myotonic Dystrophy Type 1 (DM1) Industry Trends
13.2 Myotonic Dystrophy Type 1 (DM1) Market Drivers
13.3 Myotonic Dystrophy Type 1 (DM1) Market Challenges
13.4 Myotonic Dystrophy Type 1 (DM1) Market Restraints
14 Key Findings in The Global Myotonic Dystrophy Type 1 (DM1) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Exondys
Table 3. Major Manufacturers of Emflaza
Table 4. Major Manufacturers of Translarna
Table 5. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Myotonic Dystrophy Type 1 (DM1) Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2018-2024)
Table 10. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2024-2034)
Table 11. Global Myotonic Dystrophy Type 1 (DM1) Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 12. Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2018-2024) & (Units)
Table 13. Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2024-2034) & (Units)
Table 14. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2018-2024)
Table 15. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2024-2034)
Table 16. Global Myotonic Dystrophy Type 1 (DM1) Sales by Manufacturers (2018-2024) & (Units)
Table 17. Global Myotonic Dystrophy Type 1 (DM1) Sales Share by Manufacturers (2018-2024)
Table 18. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Myotonic Dystrophy Type 1 (DM1) Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Myotonic Dystrophy Type 1 (DM1), Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Myotonic Dystrophy Type 1 (DM1) Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Myotonic Dystrophy Type 1 (DM1) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Myotonic Dystrophy Type 1 (DM1) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Type 1 (DM1) as of 2022)
Table 24. Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Product Offered and Application
Table 26. Global Key Manufacturers of Myotonic Dystrophy Type 1 (DM1), Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 29. Global Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 30. Global Myotonic Dystrophy Type 1 (DM1) Sales Share by Type (2018-2024)
Table 31. Global Myotonic Dystrophy Type 1 (DM1) Sales Share by Type (2024-2034)
Table 32. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Myotonic Dystrophy Type 1 (DM1) Revenue Share by Type (2018-2024)
Table 35. Global Myotonic Dystrophy Type 1 (DM1) Revenue Share by Type (2024-2034)
Table 36. Myotonic Dystrophy Type 1 (DM1) Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Myotonic Dystrophy Type 1 (DM1) Price Forecast by Type (2024-2034) & (US$/Unit)
Table 38. Global Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 39. Global Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 40. Global Myotonic Dystrophy Type 1 (DM1) Sales Share by Application (2018-2024)
Table 41. Global Myotonic Dystrophy Type 1 (DM1) Sales Share by Application (2024-2034)
Table 42. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Myotonic Dystrophy Type 1 (DM1) Revenue Share by Application (2018-2024)
Table 45. Global Myotonic Dystrophy Type 1 (DM1) Revenue Share by Application (2024-2034)
Table 46. Myotonic Dystrophy Type 1 (DM1) Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Myotonic Dystrophy Type 1 (DM1) Price Forecast by Application (2024-2034) & (US$/Unit)
Table 48. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 49. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 50. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 52. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 53. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 54. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 56. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 57. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2024-2034) & (US$ Million)
Table 59. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2024) & (Units)
Table 60. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales by Country (2024-2034) & (Units)
Table 61. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 62. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 63. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 65. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 66. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 67. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 69. Europe Myotonic Dystrophy Type 1 (DM1) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 70. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2024-2034) & (US$ Million)
Table 72. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2024) & (Units)
Table 73. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Country (2024-2034) & (Units)
Table 74. China Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 75. China Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 76. China Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 78. China Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 79. China Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 80. China Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 82. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 83. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 84. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 86. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 87. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 88. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 90. Asia Myotonic Dystrophy Type 1 (DM1) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 91. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2024-2034) & (US$ Million)
Table 93. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Region (2018-2024) & (Units)
Table 94. Asia Myotonic Dystrophy Type 1 (DM1) Sales by Region (2024-2034) & (Units)
Table 95. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2018-2024) & (Units)
Table 96. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2024-2034) & (Units)
Table 97. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2024-2034) & (US$ Million)
Table 99. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2018-2024) & (Units)
Table 100. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2024-2034) & (Units)
Table 101. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2024-2034) & (US$ Million)
Table 103. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 104. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2024-2034) & (US$ Million)
Table 106. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2018-2024) & (Units)
Table 107. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2024-2034) & (Units)
Table 108. Dyne Company Information
Table 109. Dyne Description and Major Businesses
Table 110. Dyne Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Dyne Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Dyne Recent Developments
Table 113. Audentes Company Information
Table 114. Audentes Description and Major Businesses
Table 115. Audentes Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Audentes Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Audentes Recent Developments
Table 118. Pfizer Company Information
Table 119. Pfizer Description and Major Businesses
Table 120. Pfizer Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Pfizer Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Pfizer Recent Developments
Table 123. Vertex Company Information
Table 124. Vertex Description and Major Businesses
Table 125. Vertex Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Vertex Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Vertex Recent Developments
Table 128. PepGen Company Information
Table 129. PepGen Description and Major Businesses
Table 130. PepGen Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. PepGen Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. PepGen Recent Developments
Table 133. NeuBase Therapeutics Company Information
Table 134. NeuBase Therapeutics Description and Major Businesses
Table 135. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. NeuBase Therapeutics Recent Developments
Table 138. Lupin Company Information
Table 139. Lupin Description and Major Businesses
Table 140. Lupin Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Lupin Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Lupin Recent Developments
Table 143. AMO Pharma Company Information
Table 144. AMO Pharma Description and Major Businesses
Table 145. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. AMO Pharma Recent Developments
Table 148. Expansion Therapeutics Company Information
Table 149. Expansion Therapeutics Description and Major Businesses
Table 150. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Expansion Therapeutics Recent Developments
Table 153. Harmony Biosciences Company Information
Table 154. Harmony Biosciences Description and Major Businesses
Table 155. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Harmony Biosciences Recent Developments
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. Myotonic Dystrophy Type 1 (DM1) Distributors List
Table 161. Myotonic Dystrophy Type 1 (DM1) Customers List
Table 162. Myotonic Dystrophy Type 1 (DM1) Market Trends
Table 163. Myotonic Dystrophy Type 1 (DM1) Market Drivers
Table 164. Myotonic Dystrophy Type 1 (DM1) Market Challenges
Table 165. Myotonic Dystrophy Type 1 (DM1) Market Restraints
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Myotonic Dystrophy Type 1 (DM1) Product Picture
Figure 2. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Type in 2022 & 2034
Figure 4. Exondys Product Picture
Figure 5. Emflaza Product Picture
Figure 6. Translarna Product Picture
Figure 7. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Application in 2022 & 2034
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Home Care
Figure 12. Myotonic Dystrophy Type 1 (DM1) Report Years Considered
Figure 13. Global Myotonic Dystrophy Type 1 (DM1) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Myotonic Dystrophy Type 1 (DM1) Revenue 2018-2034 (US$ Million)
Figure 15. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2018-2034)
Figure 17. Global Myotonic Dystrophy Type 1 (DM1) Sales 2018-2034 ((Units)
Figure 18. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2018-2034)
Figure 19. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales YoY (2018-2034) & (Units)
Figure 20. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Myotonic Dystrophy Type 1 (DM1) Sales YoY (2018-2034) & (Units)
Figure 22. Europe Myotonic Dystrophy Type 1 (DM1) Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Myotonic Dystrophy Type 1 (DM1) Sales YoY (2018-2034) & (Units)
Figure 24. China Myotonic Dystrophy Type 1 (DM1) Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Asia (excluding China) Myotonic Dystrophy Type 1 (DM1) Sales YoY (2018-2034) & (Units)
Figure 26. Asia (excluding China) Myotonic Dystrophy Type 1 (DM1) Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales YoY (2018-2034) & (Units)
Figure 28. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Myotonic Dystrophy Type 1 (DM1) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Myotonic Dystrophy Type 1 (DM1) in the World: Market Share by Myotonic Dystrophy Type 1 (DM1) Revenue in 2022
Figure 31. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 33. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 34. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 35. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 36. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 37. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 38. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 39. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 40. US & Canada Myotonic Dystrophy Type 1 (DM1) Revenue Share by Country (2018-2034)
Figure 41. US & Canada Myotonic Dystrophy Type 1 (DM1) Sales Share by Country (2018-2034)
Figure 42. U.S. Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 45. Europe Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 46. Europe Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 47. Europe Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 48. Europe Myotonic Dystrophy Type 1 (DM1) Revenue Share by Country (2018-2034)
Figure 49. Europe Myotonic Dystrophy Type 1 (DM1) Sales Share by Country (2018-2034)
Figure 50. Germany Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 51. France Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 52. U.K. Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 53. Italy Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 54. Russia Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 55. China Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 56. China Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 57. China Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 58. China Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 59. Asia Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 60. Asia Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 61. Asia Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 62. Asia Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 63. Asia Myotonic Dystrophy Type 1 (DM1) Revenue Share by Region (2018-2034)
Figure 64. Asia Myotonic Dystrophy Type 1 (DM1) Sales Share by Region (2018-2034)
Figure 65. Japan Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 66. South Korea Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 67. China Taiwan Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 68. Southeast Asia Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 69. India Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2018-2034)
Figure 71. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2018-2034)
Figure 73. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Revenue Share by Country (2018-2034)
Figure 75. Middle East, Africa and Latin America Myotonic Dystrophy Type 1 (DM1) Sales Share by Country (2018-2034)
Figure 76. Brazil Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 77. Mexico Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 78. Turkey Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 79. Israel Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 80. GCC Countries Myotonic Dystrophy Type 1 (DM1) Revenue (2018-2034) & (US$ Million)
Figure 81. Myotonic Dystrophy Type 1 (DM1) Value Chain
Figure 82. Myotonic Dystrophy Type 1 (DM1) Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed